STERIS PLC (NYSE:STE) had its price target raised by equities research analysts at Raymond James Financial, Inc. from $95.00 to $100.00 in a research report issued to clients and investors on Monday, October 16th. The brokerage currently has an “outperform” rating on the medical equipment provider’s stock. Raymond James Financial, Inc.’s target price indicates a potential upside of 7.76% from the company’s current price.
Several other analysts have also commented on the company. Zacks Investment Research raised STERIS PLC from a “hold” rating to a “buy” rating and set a $101.00 target price on the stock in a report on Monday, October 9th. BidaskClub lowered STERIS PLC from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. STERIS PLC has a consensus rating of “Buy” and a consensus target price of $90.75.
STERIS PLC (STE) opened at 92.80 on Monday. STERIS PLC has a 12 month low of $63.80 and a 12 month high of $92.96. The firm has a market cap of $7.91 billion, a P/E ratio of 66.38 and a beta of 1.29. The stock has a 50 day moving average of $88.76 and a 200-day moving average of $82.06.
STERIS PLC (NYSE:STE) last posted its earnings results on Tuesday, August 8th. The medical equipment provider reported $0.85 EPS for the quarter, topping the consensus estimate of $0.80 by $0.05. The firm had revenue of $608.00 million for the quarter, compared to analyst estimates of $597.66 million. STERIS PLC had a return on equity of 11.39% and a net margin of 4.63%. STERIS PLC’s revenue for the quarter was down 4.8% compared to the same quarter last year. During the same period last year, the company earned $0.79 earnings per share. Equities research analysts predict that STERIS PLC will post $4.06 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Raymond James Financial, Inc. Raises STERIS PLC (STE) Price Target to $100.00” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/10/28/raymond-james-financial-inc-raises-steris-plc-ste-price-target-to-100-00.html.
In other news, insider Michael J. Tokich sold 11,000 shares of the firm’s stock in a transaction that occurred on Monday, October 23rd. The stock was sold at an average price of $92.00, for a total value of $1,012,000.00. Following the transaction, the insider now owns 58,588 shares in the company, valued at $5,390,096. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Mohsen Sohi sold 2,744 shares of the firm’s stock in a transaction that occurred on Wednesday, August 9th. The shares were sold at an average price of $85.98, for a total value of $235,929.12. Following the completion of the transaction, the director now owns 21,816 shares in the company, valued at approximately $1,875,739.68. The disclosure for this sale can be found here. Insiders have sold 205,086 shares of company stock worth $17,965,621 in the last quarter. 2.55% of the stock is currently owned by company insiders.
Institutional investors have recently made changes to their positions in the stock. Citigroup Inc. purchased a new position in STERIS PLC during the second quarter worth approximately $206,000. Van Cleef Asset Management Inc purchased a new position in STERIS PLC during the second quarter worth approximately $208,000. Cigna Investments Inc. New purchased a new position in STERIS PLC during the second quarter worth approximately $209,000. BT Investment Management Ltd purchased a new position in STERIS PLC during the second quarter worth approximately $210,000. Finally, Allegis Investment Advisors LLC purchased a new position in STERIS PLC during the second quarter worth approximately $251,000. Hedge funds and other institutional investors own 94.13% of the company’s stock.
STERIS PLC Company Profile
STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others.
Receive News & Ratings for STERIS PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS PLC and related companies with MarketBeat.com's FREE daily email newsletter.